IL278185A - - Google Patents

Info

Publication number
IL278185A
IL278185A IL27818520A IL27818520A IL278185A IL 278185 A IL278185 A IL 278185A IL 27818520 A IL27818520 A IL 27818520A IL 27818520 A IL27818520 A IL 27818520A IL 278185 A IL278185 A IL 278185A
Authority
IL
Israel
Application number
IL27818520A
Other languages
English (en)
Other versions
IL278185B2 (en
IL278185B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL278185A publication Critical patent/IL278185A/en
Publication of IL278185B1 publication Critical patent/IL278185B1/en
Publication of IL278185B2 publication Critical patent/IL278185B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL278185A 2018-04-25 2019-04-24 Tetrabenazine transdermal delivery device IL278185B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862662456P 2018-04-25 2018-04-25
PCT/US2019/028900 WO2019209940A1 (en) 2018-04-25 2019-04-24 Tetrabenazine transdermal delivery device

Publications (3)

Publication Number Publication Date
IL278185A true IL278185A (https=) 2020-12-31
IL278185B1 IL278185B1 (en) 2024-07-01
IL278185B2 IL278185B2 (en) 2024-11-01

Family

ID=68295781

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278185A IL278185B2 (en) 2018-04-25 2019-04-24 Tetrabenazine transdermal delivery device

Country Status (15)

Country Link
US (2) US12144899B2 (https=)
EP (1) EP3784237B1 (https=)
JP (1) JP7386544B2 (https=)
KR (1) KR102952482B1 (https=)
CN (1) CN112165942B (https=)
AU (1) AU2019261403B2 (https=)
BR (1) BR112020021700A2 (https=)
CA (1) CA3097189A1 (https=)
DK (1) DK3784237T3 (https=)
ES (1) ES2968827T3 (https=)
IL (1) IL278185B2 (https=)
MX (1) MX2020011269A (https=)
TW (1) TWI832854B (https=)
WO (1) WO2019209940A1 (https=)
ZA (1) ZA202006415B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3784237B1 (en) 2018-04-25 2023-11-01 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
US20220362165A1 (en) * 2019-10-22 2022-11-17 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
IL296624A (en) * 2020-03-30 2022-11-01 Shinkei Therapeutics Inc Transdermal delivery of dextromethorphan
CN116036055A (zh) * 2023-03-16 2023-05-02 上海世领制药有限公司 一种含甲磺酸雷沙吉兰的透皮贴剂及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63313723A (ja) 1987-06-16 1988-12-21 Nitto Electric Ind Co Ltd 外用貼付剤
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
JP4988080B2 (ja) * 1997-09-05 2012-08-01 日東電工株式会社 経皮吸収型製剤
IL135258A0 (en) 1997-09-26 2001-05-20 Noven Pharma Bioadhesive compositions and methods for topical administration of active agents
WO2002024157A2 (en) * 2000-09-19 2002-03-28 National Starch And Chemical Investment Holding Corporation Acryl adhesive useful in transdermal drug delivery systems
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
TW200628175A (en) 2004-10-08 2006-08-16 Noven Pharma Transdermal drug delivert device including an occlusive backing
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
GB0514501D0 (en) 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2771539A1 (en) 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
DE102010024105A1 (de) 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
HK1206297A1 (en) 2012-04-04 2016-01-08 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
EP2872126B1 (en) * 2012-07-16 2017-12-06 Grünenthal GmbH Pharmaceutical patch for transdermal administration of tapentadol
US9682068B2 (en) 2013-05-20 2017-06-20 Mylan Inc. Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders
WO2014195352A1 (en) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
EA201691512A1 (ru) 2014-01-27 2017-01-30 Оспекс Фармасьютикалз, Инк. Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2
NZ760790A (en) 2014-02-07 2022-11-25 Neurocrine Biosciences Inc Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
WO2015171802A1 (en) * 2014-05-06 2015-11-12 Neurocrine Biosciences, Inc. Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
AR098771A1 (es) * 2014-12-16 2016-06-15 Amarin Tech S A Un dispositivo para la administración transdérmica de rotigotina
HRP20221106T1 (hr) 2015-03-06 2022-11-25 Auspex Pharmaceuticals, Inc. Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
EA036837B1 (ru) 2015-06-23 2020-12-25 Нейрокрин Байосайенсиз, Инк. Ингибиторы vmat2 для лечения неврологических заболеваний или расстройств
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN107028916B (zh) * 2016-02-04 2020-05-12 北京泰德制药股份有限公司 含有布比卡因或其药用盐的皮肤外用制剂
ITUB20161016A1 (it) * 2016-02-24 2017-08-24 Emenem Srl Composizioni farmaceutiche o cosmetiche comprendenti un polimero e un promotore di assorbimento per il rilascio controllato di principi attivi
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
CN110678181A (zh) 2017-04-01 2020-01-10 阿德普蒂奥制药有限公司 (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
US20190111035A1 (en) 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
TWI741168B (zh) * 2017-04-28 2021-10-01 日商日東電工股份有限公司 經皮吸收製劑
WO2019016357A1 (en) 2017-07-20 2019-01-24 Neurolixis USE OF SELECTIVE 5-HT1A SEROTONIN RECEPTOR AGONISTS TO TREAT THE ADVERSE EFFECTS OF VMAT INHIBITORS
GB2565049B (en) 2017-07-27 2020-06-10 Reckitt Benckiser Health Ltd A head assembly of a dermaplaning device
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 特定のvmat2インヒビターを投与するための方法
EP3784237B1 (en) 2018-04-25 2023-11-01 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
US20190374521A1 (en) 2018-06-10 2019-12-12 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.

Also Published As

Publication number Publication date
KR102952482B1 (ko) 2026-04-13
ES2968827T3 (es) 2024-05-14
ZA202006415B (en) 2024-04-24
TW202014187A (zh) 2020-04-16
BR112020021700A2 (pt) 2021-01-26
KR20210005623A (ko) 2021-01-14
EP3784237A1 (en) 2021-03-03
EP3784237A4 (en) 2022-02-16
TWI832854B (zh) 2024-02-21
IL278185B2 (en) 2024-11-01
WO2019209940A1 (en) 2019-10-31
AU2019261403A1 (en) 2020-11-12
MX2020011269A (es) 2020-12-11
US20250144045A1 (en) 2025-05-08
CN112165942A (zh) 2021-01-01
US20210128490A1 (en) 2021-05-06
DK3784237T3 (da) 2024-01-08
CA3097189A1 (en) 2019-10-31
JP7386544B2 (ja) 2023-11-27
AU2019261403B2 (en) 2025-05-15
CN112165942B (zh) 2024-04-12
US12144899B2 (en) 2024-11-19
JP2021522240A (ja) 2021-08-30
IL278185B1 (en) 2024-07-01
EP3784237B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
BR112021012225A2 (https=)
BR112021008873A2 (https=)
BR122022006221A2 (https=)
BR112021000792B8 (https=)
BR122022015534A2 (https=)
BR122022002075A2 (https=)
IL278185A (https=)
BR122022005529A2 (https=)
BR122022016585A2 (https=)
BR212020012832U2 (https=)
BR202018071071U8 (https=)
BR102018070765A2 (https=)
BR102018016915A2 (https=)
BR112020025288A2 (https=)
BR202018008879U2 (https=)
BR202018007669U2 (https=)
BR202018006247U2 (https=)
BR202018004136U2 (https=)
BR202018002487U2 (https=)
BR202018002069U2 (https=)
CN304448325S (https=)
CN304436314S (https=)
CN303588531S9 (https=)
CN304445525S (https=)
CN304201967S8 (https=)